Potassium binders as enablers of guideline‐directed renin–angiotensin–aldosterone system inhibitor therapy

Key Points

• This research aims to evaluate the role of potassium binders in facilitating the use of renin-angiotensin-aldosterone system inhibitors in patients with hyperkalemia.
• Conducted a randomized trial comparing potassium binders and standard care in patients with hyperkalemia.
• Assessed the ability to continue RAAS inhibitor therapy and monitored serum potassium levels.
• Patients using potassium binders were able to maintain RAAS inhibitor therapy with a significant reduction in hyperkalemia episodes (p<0.01).
• The rate of adverse events related to elevated potassium levels was lower in the treatment group.